A new trial has shown promising results for an oral GLP-1 drug called aleniglipron, which may potentially treat overweight or obesity. The trial, which was randomized, double-blind, and placebo-controlled, reportedly delivered significant weight loss. The outcomes of the trial have been described as positive, with some outlets suggesting the drug could be a competitive option in its class.